Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory, High Risk Hematologic Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01757639
What this trial is testing

Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome+3 more
National Cancer Institute (NCI) 42
Early research (Phase 1)Looking for participantsNCT03896269
What this trial is testing

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Who this might be right for
Blasts 10-19 Percent of Bone Marrow Nucleated CellsBlasts More Than 5 Percent of Bone Marrow Nucleated CellsHigh Risk Chronic Myelomonocytic Leukemia+4 more
M.D. Anderson Cancer Center 38
Testing effectiveness (Phase 2)Study completedNCT00002630
What this trial is testing

High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Mayo Clinic 50
Early research (Phase 1)Looking for participantsNCT06544265
What this trial is testing

SynKIR-310 for Relapsed/Refractory B-NHL

Who this might be right for
B Cell LymphomaNHL, AdultMantle Cell Lymphoma+23 more
Verismo Therapeutics 36
Testing effectiveness (Phase 2)Ended earlyNCT00583102
What this trial is testing

Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML

Who this might be right for
Acute Myeloid Leukemia
University of Iowa 23
Testing effectiveness (Phase 2)Looking for participantsNCT06948084
What this trial is testing

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Who this might be right for
Recurrent Multiple MyelomaRefractory Multiple Myeloma
National Cancer Institute (NCI) 80
Early research (Phase 1)Study completedNCT00459212
What this trial is testing

GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia

Who this might be right for
Acute Undifferentiated LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)+13 more
National Cancer Institute (NCI) 24
Early research (Phase 1)Ended earlyNCT00725062
What this trial is testing

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Who this might be right for
Graft Versus Host DiseaseLeukemiaLymphoma+2 more
Masonic Cancer Center, University of Minnesota 3
Early research (Phase 1)Ended earlyNCT01408160
What this trial is testing

Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
Adult B Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic Leukemia
Albert Einstein College of Medicine 18
Testing effectiveness (Phase 2)Study completedNCT03793140
What this trial is testing

CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

Who this might be right for
LymphomaLeukemia
Memorial Sloan Kettering Cancer Center 24
Early research (Phase 1)Study completedNCT02484391
What this trial is testing

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

Who this might be right for
Granulocytic SarcomaRecurrent Adult Acute Myeloid Leukemia
Wake Forest University Health Sciences 48
Early research (Phase 1)Study completedNCT00002588
What this trial is testing

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia

Who this might be right for
Leukemia
Case Comprehensive Cancer Center 30
Early research (Phase 1)Ended earlyNCT02057770
What this trial is testing

Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Leukemia, Myeloid, Acute
Washington University School of Medicine 25
Early research (Phase 1)Looking for participantsNCT04275518
What this trial is testing

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)
Ascentage Pharma Group Inc. 102
Testing effectiveness (Phase 2)Study completedNCT01191190
What this trial is testing

Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)

Who this might be right for
CLL
Januario Castro, M.D. 21
Testing effectiveness (Phase 2)Study completedNCT01177371
What this trial is testing

High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Megakaryoblastic Leukemia (M7)+70 more
Case Comprehensive Cancer Center 13
Testing effectiveness (Phase 2)Study completedNCT04432506
What this trial is testing

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

Who this might be right for
Hematopoietic and Lymphoid Cell NeoplasmRecurrent Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma+6 more
M.D. Anderson Cancer Center 22
Early research (Phase 1)Study completedNCT05829226
What this trial is testing

Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Who this might be right for
AML, Adult RecurrentMDS
PureTech 101
Testing effectiveness (Phase 2)Study completedNCT02649790
What this trial is testing

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Who this might be right for
Relapsed/Refractory Multiple Myeloma (RRMM)Metastatic Colorectal Cancer (mCRC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)+3 more
Karyopharm Therapeutics Inc 277
Testing effectiveness (Phase 2)Study completedNCT01692197
What this trial is testing

E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 43
Next Page